【一品红：全资子公司创新药APH03621片获得临床试验批准通知书 目前国内暂无获批上市的GnRH口 服小分子拮抗剂】智通财经10月24日电，一品红(300723.SZ)公告称，公司全资子公司广州一品红制药 有限公司自主研发的创新药物APH03621片的药物临床试验申请已获得国家药品监督管理局批准，并收 到《药物临床试验批准通知书》，将于近期开展临床试验。APH03621片为一种新型口服、非肽类小分 子促性腺激素释放激素受体拮抗剂（GnRH-ant），拟用于子宫内膜异位症治疗。目前国内暂无获批上 市的GnRH口服小分子拮抗剂。 转自：智通财经 ...

证券代码：300723 证券简称：一品红 公告编号：2025-066 一品红药业集团股份有限公司 关于全资子公司创新药 APH03621 片获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，一品红药业集团股份有限公司（以下简称"公司"）全资子公司广州 一品红制药有限公司自主研发的创新药物 APH03621 片的药物临床试验申请已获 得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，将于近期开 展临床试验。现将相关情况公告如下： 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 8 月 1 日受理的 APH03621 片临床试验申请符合药品注册的有关要求，同意本 品开展临床研究。 二、药品研发及相关情况 下丘脑和垂体是 GnRH 的主要来源和目标部位。然而，垂体外和下丘脑外的 GnRH 受体也存在于各种生殖器官中，如子宫肌层、子宫内膜和卵巢。GnRH 通过 多种机制，包括组织重塑，以旁分泌和自分泌的方式控制胚胎着床和初始阶段子 宫内膜细胞的增殖和运动。从药理学分类来看，本品属于生殖系统的性激素 ...

一品红公告，全资子公司广州一品红制药有限公司自主研发的创新药物APH03621片的药物临床试验申 请已获得国家药品监督管理局批准，并收到《药物临床试验批准通知书》，将于近期开展临床试验。 APH03621是公司研制的一种新型口服、非肽类小分子促性腺激素释放激素受体拮抗剂（GnRH-ant）， 拟用于子宫内膜异位症治疗。目前，国内暂无获批上市的GnRH口服小分子拮抗剂。APH03621片获得 临床试验批准对公司短期的财务状况、经营业绩不构成重大影响。 ...

Core Points - The stock price of Yipinhong has decreased by 2.01% to 52.12 CNY per share as of October 24, with a total market capitalization of 23.542 billion CNY [1] - Year-to-date, Yipinhong's stock has increased by 205.51%, but it has seen a decline of 6.17% in the last five trading days, 14.23% in the last 20 days, and 30.61% in the last 60 days [2] - The company has reported a significant drop in revenue and net profit for the first half of 2025, with revenue of 584 million CNY, a decrease of 36.02%, and a net loss of 73.542 million CNY, a decrease of 258.30% [2] Financial Performance - Yipinhong's main business revenue composition includes 61.12% from children's medicine, 22.71% from chronic disease medicine, and 16.17% from other products [2] - The company has distributed a total of 335 million CNY in dividends since its A-share listing, with 151 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, the number of shareholders for Yipinhong is 18,900, a decrease of 11.34% from the previous period, with an average of 22,055 circulating shares per shareholder, an increase of 12.79% [2] - The eighth largest circulating shareholder is E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares as a new shareholder, while Hong Kong Central Clearing Limited has exited the top ten circulating shareholders [3]

Group 1 - The core point of the news is that Yipinhong Pharmaceutical Group experienced a decline in stock price, dropping by 5.05% to 53.20 CNY per share, with a trading volume of 254 million CNY and a turnover rate of 1.12%, resulting in a total market capitalization of 24.03 billion CNY [1] - Yipinhong Pharmaceutical, established on February 4, 2002, and listed on November 16, 2017, is located in Guangzhou, Guangdong Province. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1] - The company's main business revenue composition includes children's medicine at 61.12%, chronic disease medicine at 22.71%, and other products at 16.17% [1] Group 2 - From the perspective of major fund holdings, the Dongfang Alpha Fund has a significant position in Yipinhong, with the Dongfang Alpha Health Industry Mixed Fund A (024357) holding 15,700 shares, accounting for 7.76% of the fund's net value, making it the third-largest holding [2] - The Dongfang Alpha Health Industry Mixed Fund A (024357) was established on June 12, 2025, with a latest scale of 9.5635 million CNY and has experienced a loss of 1.01% since inception [2] - The fund manager, Meng Yu, has been in the position for 1 year and 330 days, with total fund assets of 169 million CNY, achieving a best fund return of 22.64% and a worst fund return of -0.41% during the tenure [2]

Core Insights - The article highlights the significant performance of certain funds in the third quarter, particularly the "Yongying Technology Smart Selection" fund, which achieved a remarkable 194% increase, making it the top-performing fund of the year [1][2] - The report indicates a substantial growth in fund size, with "Yongying Technology Smart Selection" increasing from 1.166 billion to 11.521 billion yuan, nearly a ninefold increase in a single quarter [2] - The article also discusses the ongoing optimism in the innovative pharmaceutical sector, with funds like "Great Wall Pharmaceutical Industry Selection" showing over 100% growth [1][4] Fund Performance - "Yongying Technology Smart Selection" fund's top holdings include leading optical module stocks such as "Yizhongtian" (Xinyi Sheng, 300502), Zhongji Xuchuang (300308), and Tianfu Communication (300394), which significantly contributed to its net value [2] - The fund's share count surged from 700 million to 3.466 billion, resulting in a profit of 4.715 billion yuan for investors in the third quarter [2] - The "Great Wall Pharmaceutical Industry Selection" fund also saw its size grow from 1.132 billion to 1.790 billion yuan, with a share increase from 678 million to 932 million [5] Sector Insights - The global cloud computing industry remains a focal point, with AI model valuations increasing and a notable 100% quarter-on-quarter growth in token numbers [3] - The innovative pharmaceutical sector continues to attract attention, with funds maintaining high stock positions despite recent market adjustments [6][8] - The article suggests that the technology and pharmaceutical sectors may still have upward potential, although careful stock selection is advised [8] Future Outlook - The article indicates that the technology sector, particularly AI and cloud computing, is expected to see increased investment, with potential for new opportunities in the industry chain [9] - The innovative pharmaceutical sector is projected to strengthen its global competitiveness, supported by upcoming industry conferences and positive data trends [8] - The article emphasizes the importance of not solely relying on past performance to predict future outcomes in the cloud computing sector, highlighting the need for caution [9]

Group 1: Fund Performance and Holdings - The performance of the "Champion Fund" Yongying Technology Smart Selection has seen a remarkable increase, with a year-to-date return of nearly 195% and a net asset value growth of 234% since its inception [2][3][9] - The fund's scale surged nearly tenfold in the third quarter, growing from 1.166 billion to 11.521 billion yuan, with the number of shares increasing from 700 million to 3.466 billion [5][9] - The fund maintains a high stock position, with over 91% in equities, focusing heavily on the cloud computing sector [2][3] Group 2: Key Holdings in Cloud Computing - The top three holdings of Yongying Technology Smart Selection include Xinyi Technology, Zhongji Xuchuang, and Tianfu Communication, each with a market value exceeding 1 billion yuan [3][2] - Significant increases in holdings were observed for Huadian Co., Taicheng Light, and Tianfu Communication, with growth rates of 502.17%, 642.80%, and 347.47% respectively [3][2] Group 3: Longcheng Pharmaceutical Industry Selection - Longcheng Pharmaceutical Industry Selection has also performed well, achieving a return of 102.02% in the first three quarters, qualifying it as a "doubling fund" [7][9] - The fund's scale increased from 1.132 billion to 1.790 billion yuan in the third quarter, marking a growth of nearly 60% [9] - The fund's top three holdings include Innovent Biologics, 3SBio, and Hotgen Biotech, with each holding a market value exceeding 100 million yuan [8][7] Group 4: Investment Focus and Strategy - The investment strategy of Yongying Technology Smart Selection emphasizes the cloud computing industry, with a focus on optical communication and PCB sectors, anticipating significant technological advancements by 2027 [6][2] - Longcheng Pharmaceutical Industry Selection is shifting its focus towards clinical data, overseas licensing, and domestic sales, indicating a strategic pivot towards non-oncology sectors [9][7]

Core Viewpoint - Yipinhong's stock price has experienced significant fluctuations this year, with a year-to-date increase of 215.59%, but recent trends show a decline in the short term [2]. Group 1: Stock Performance - On October 21, Yipinhong's stock fell by 2.04%, trading at 53.84 CNY per share, with a total market capitalization of 24.319 billion CNY [1]. - The stock has seen a 1.62% increase over the last five trading days, a 13.45% decrease over the last 20 days, and a 33.14% decrease over the last 60 days [2]. Group 2: Financial Metrics - For the first half of 2025, Yipinhong reported a revenue of 584 million CNY, a year-on-year decrease of 36.02%, and a net profit attributable to shareholders of -73.5422 million CNY, a decrease of 258.30% [2]. - The company has distributed a total of 335 million CNY in dividends since its A-share listing, with 151 million CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 30, the number of Yipinhong's shareholders was 18,900, a decrease of 11.34% from the previous period, with an average of 22,055 circulating shares per shareholder, an increase of 12.79% [2]. - As of June 30, 2025, Yipinhong's top ten circulating shareholders included a new entry, E Fund Medical Healthcare Industry Mixed A, holding 4.3661 million shares [3].

Core Viewpoint - Yipin Hong (300723) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Chloride Injection from the National Medical Products Administration, indicating a significant regulatory approval for the company [1] Company Summary - The approved product, Methacholine Chloride Injection, is indicated for the antagonism of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery, as well as for conditions such as myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1] - According to data from Minet, the sales scale of Methacholine Chloride in urban and county-level public hospitals in China is projected to be approximately 791 million yuan in 2024 [1]

Core Viewpoint - Yipinhong (300723.SZ) announced that its wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has received the drug registration certificate for Methacholine Injection from the National Medical Products Administration, indicating a significant regulatory approval for a new product in its portfolio [1] Group 1: Product Details - Methacholine Injection is indicated for the reversal of residual muscle relaxation effects from non-depolarizing muscle relaxants at the end of surgery, treatment of myasthenia gravis, postoperative functional intestinal distension, and urinary retention [1] - Methacholine is classified as a competitive acetylcholinesterase inhibitor, which works by reducing the breakdown of acetylcholine, thereby increasing its availability in the synaptic cleft to compete with non-depolarizing neuromuscular blockers [1]